These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

403 related articles for article (PubMed ID: 9512334)

  • 21. Second-look laparotomy for ovarian cancer provides reliable prognostic information and improves survival.
    Friedman RL; Eisenkop SM; Wang HJ
    Gynecol Oncol; 1997 Oct; 67(1):88-94. PubMed ID: 9345362
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The role of secondary cytoreductive surgery for recurrent ovarian cancer.
    Güngör M; Ortaç F; Arvas M; Kösebay D; Sönmezer M; Köse K
    Gynecol Oncol; 2005 Apr; 97(1):74-9. PubMed ID: 15790440
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Recurrent and 2nd line therapy in ovarian carcinoma: an overview of conventional systemic therapy modalities].
    du Bois A; Lück HJ; Meerpohl HG
    Zentralbl Gynakol; 1997; 119(7):299-323. PubMed ID: 9340970
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Secondary cytoreductions in the treatment of ovarian cancers].
    Zylberberg B; Dormont D; Janklewicz S; Daraï E; Madelenat P; Antoine JM
    Gynecol Obstet Fertil; 2000 Feb; 28(2):127-36. PubMed ID: 10758587
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Impact of second look laparotomy and secondary cytoreductive surgery at second-look laparotomy in ovarian cancer patients.
    Obermair A; Sevelda P
    Acta Obstet Gynecol Scand; 2001 May; 80(5):432-6. PubMed ID: 11328220
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The benefits of comprehensive surgical staging in the management of early-stage epithelial ovarian carcinoma.
    Le T; Adolph A; Krepart GV; Lotocki R; Heywood MS
    Gynecol Oncol; 2002 May; 85(2):351-5. PubMed ID: 11972399
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Secondary cytoreductive surgery for patients with recurrent epithelial ovarian carcinoma.
    Scarabelli C; Gallo A; Carbone A
    Gynecol Oncol; 2001 Dec; 83(3):504-12. PubMed ID: 11733963
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Relationship between time interval from primary surgery to the start of taxane- plus platinum-based chemotherapy and clinical outcome of patients with advanced epithelial ovarian cancer: results of a multicenter retrospective Italian study.
    Gadducci A; Sartori E; Landoni F; Zola P; Maggino T; Maggioni A; Cosio S; Frassi E; LaPresa MT; Fuso L; Cristofani R
    J Clin Oncol; 2005 Feb; 23(4):751-8. PubMed ID: 15613698
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Hyperthermic intraperitoneal chemotherapy in conjunction with surgery for the treatment of recurrent ovarian carcinoma.
    Helm CW; Randall-Whitis L; Martin RS; Metzinger DS; Gordinier ME; Parker LP; Edwards RP
    Gynecol Oncol; 2007 Apr; 105(1):90-6. PubMed ID: 17173957
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Factors affecting disease recurrence and the role of secondary therapies in the management for patients with recurrent ovarian carcinoma].
    Zang R; Zhang Z; Cai S
    Zhonghua Fu Chan Ke Za Zhi; 2002 Sep; 37(9):546-9. PubMed ID: 12411017
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The benefits of low anterior en bloc resection as part of cytoreductive surgery for advanced primary and recurrent epithelial ovarian cancer patients outweigh morbidity concerns.
    Park JY; Seo SS; Kang S; Lee KB; Lim SY; Choi HS; Park SY
    Gynecol Oncol; 2006 Dec; 103(3):977-84. PubMed ID: 16837030
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Second-line treatment with carboplatin for recurrent or progressive oligodendroglial tumors after PCV (procarbazine, lomustine, and vincristine) chemotherapy: a phase II study.
    Soffietti R; Nobile M; Rudà R; Borgognone M; Costanza A; Laguzzi E; Mutani R
    Cancer; 2004 Feb; 100(4):807-13. PubMed ID: 14770438
    [TBL] [Abstract][Full Text] [Related]  

  • 33. High-dose melphalan-based chemotherapy and autologous stem cell transplantation after second look laparotomy in patients with chemosensitive advanced ovarian carcinoma: long-term results.
    Bertucci F; Viens P; Delpero JR; Bardou VJ; Faucher C; Houvenaeghel G; Maraninchi D
    Bone Marrow Transplant; 2000 Jul; 26(1):61-7. PubMed ID: 10918406
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The role of secondary cytoreductive surgery for recurrent mucinous epithelial ovarian cancer (mEOC).
    Cheng X; Jiang R; Li ZT; Tang J; Cai SM; Zhang ZY; Tian WJ; Zang RY
    Eur J Surg Oncol; 2009 Oct; 35(10):1105-8. PubMed ID: 19443175
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A formula for predicting the risk of a positive second-look laparotomy in epithelial ovarian cancer: implications for a randomized trial.
    Morgan MA; Noumoff JS; King S; Mikuta JJ
    Obstet Gynecol; 1992 Dec; 80(6):944-8. PubMed ID: 1333064
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Evidence for a dose-response effect between p53 (but not p21WAF1/Cip1) protein concentrations, survival, and responsiveness in patients with epithelial ovarian cancer treated with platinum-based chemotherapy.
    Levesque MA; Katsaros D; Massobrio M; Genta F; Yu H; Richiardi G; Fracchioli S; Durando A; Arisio R; Diamandis EP
    Clin Cancer Res; 2000 Aug; 6(8):3260-70. PubMed ID: 10955812
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Surgical cytoreduction in recurrent ovarian carcinoma in patients with complete response to paclitaxel-platinum.
    Gronlund B; Lundvall L; Christensen IJ; Knudsen JB; Høgdall C
    Eur J Surg Oncol; 2005 Feb; 31(1):67-73. PubMed ID: 15642428
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Safety of cisplatin after severe hypersensitivity reactions to carboplatin in patients with recurrent ovarian carcinoma.
    Ottaiano A; Tambaro R; Greggi S; Prato R; Di Maio M; Esposito G; Scala F; Barletta E; Losito S; De Vivo R; Iaffaioli VR; Pignata S
    Anticancer Res; 2003; 23(4):3465-8. PubMed ID: 12926091
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Efficacy and hematologic toxicity of salvage chemotherapy following stem cell-supported high-dose chemotherapy in women with recurrent ovarian cancer.
    Cook S; Penson R; Duska L; Nikrui N; Goodman A; Fuller A; Seiden M
    Gynecol Oncol; 2000 Apr; 77(1):48-54. PubMed ID: 10739690
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Recurrent epithelial ovarian cancer].
    Ding X; Lang J; Shen K
    Zhonghua Fu Chan Ke Za Zhi; 1999 Jan; 34(1):30-2. PubMed ID: 11263170
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 21.